Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma, Inc. reported that its Chief Medical Officer, Robert Redfield, received new equity awards in the company’s stock. On 12/12/2025 he acquired 16,419 shares of common stock for $0 as an award of restricted stock units that vest 100% on the first anniversary of the grant date, bringing his directly owned common shares to 113,919.
He was also granted 65,676 stock options with an exercise price of $2.33 per share. These options become exercisable on 12/12/2026, expire on 12/12/2035, and relate to 65,676 shares of common stock. The restricted stock units convert into common stock on a one-for-one basis once vested, tying a portion of his compensation to the company’s share performance.
Traws Pharma director and chief operating officer Nikolay Savchuk reported new equity awards. On 12/12/2025, he received 16,419 restricted stock units of Traws Pharma common stock at $0, increasing his direct holdings to 150,606 shares.
The same day, he was granted stock options to buy 65,676 Traws Pharma shares at an exercise price of $2.33. Both the restricted stock units and the options vest 100% on the first anniversary of the 12/12/2025 grant date, providing additional long-term equity-based compensation.
Traws Pharma, Inc. granted new stock options and restricted stock units to its executive leadership on December 12, 2025. Grants include 147,771 options and 36,943 RSUs for CEO Iain Dukes, 61,571 options and 15,393 RSUs for CFO Charles Parker, 73,886 options and 18,471 RSUs for Chief Science Officer C. David Pauza, and 65,676 options and 16,419 RSUs each for Chief Medical Officer Robert Redfield and Chief Operating Officer Nikolay Savchuk. The options have a $2.33 per share exercise price (the closing price on December 12, 2025), a ten-year term, and vest in full on the first anniversary of the grant date, subject to continued service, with all awards granted under the Amended and Restated 2021 Incentive Compensation Plan.
Traws Pharma, Inc. (TRAW) reported an equity compensation grant to one of its directors, John Leaman. On 11/21/2025, he was granted a stock option to purchase 12,770 shares of Traws Pharma common stock at an exercise price of $2.31 per share. The option is held directly and expires on 11/21/2035.
The option vests over three years from the grant date, with 33% vesting on the first anniversary, 33% on the second anniversary, and the remaining 34% on the third anniversary. Following this grant, John Leaman beneficially owns 12,770 derivative securities in the form of these stock options.
Traws Pharma, Inc. reported Q3 results showing a net loss of $3.96 million as R&D and G&A totaled $2.31 million and $1.74 million, respectively. Cash and cash equivalents were $6.42 million at September 30, 2025, with total assets of $12.44 million. Stockholders’ equity improved to $4.55 million, aided by a sharp reduction in warrant liabilities.
For the nine months, the company recorded net income of $16.61 million, driven primarily by a $26.66 million non‑cash gain from the change in fair value and reclassification of warrant liabilities, and recognition of $2.79 million in revenue upon the termination of a legacy license. Operating cash outflow was $15.43 million year‑to‑date.
The company entered an ATM Agreement authorizing sales of up to $50 million in common stock and raised $3.27 million net by issuing 1,627,050 shares. It also acquired IP assets from Viriom for $2.35 million in cash, adding a patent now carried at $2.57 million. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern based on current cash projections.
Traws Pharma (TRAW) furnished an update on November 13, 2025 announcing it issued a press release with financial results for the quarter ended September 30, 2025 and began using a new corporate presentation. Both materials were provided as Exhibits 99.1 and 99.2.
The materials under Item 7.01 are being furnished, not filed, which means they are not subject to Section 18 liability and are not incorporated into other filings unless specifically referenced. The company also included standard forward-looking statements language.
Traws Pharma (TRAW) reported executive equity grants. On October 12, 2025, the board’s Compensation Committee approved stock options for five executives at an exercise price of $3.01 per share, each with a 10‑year term and one‑year cliff vesting (vesting in full on the first anniversary, subject to continued service). Grants include 64,839 options to the CEO, and 32,406 each to the CFO, Chief Science Officer (Virology), and Chief Medical Officer, plus 22,435 to the COO. Awards were made under the Amended and Restated 2021 Incentive Compensation Plan.
Traws Pharma (TRAW) reported an insider equity award. Chief Science Officer, Virology, Charles David Pauza acquired 32,406 stock options at an exercise price of $3.01 on 10/12/2025, as disclosed on Form 4.
The options vest 100% on 10/12/2026 and expire on 10/12/2035. Following the transaction, the reporting person beneficially owns 32,406 derivative securities directly. This reflects routine equity compensation.
Traws Pharma (TRAW) reported a director stock option grant on 10/12/2025. The filing shows a grant of 11,530 stock options with an exercise price of $3.01 per share. The options vest 100% on 10/12/2026 and expire on 10/12/2035.
Following the transaction, the reporting person held 11,530 derivative securities, with ownership listed as Direct. This was a routine equity award; no common shares were listed in the non-derivative table.
Traws Pharma, Inc. filed a Form 4 reporting a director stock option grant. On 10/12/2025, the reporting person received a stock option to purchase 11,530 shares of common stock at an exercise price of $3.01 per share.
The option vests 100% on 10/12/2026 and expires on 10/12/2035. Following this grant, 11,530 derivative securities were beneficially owned on a direct basis. The filing lists no transactions in non-derivative common stock.
FAQ
What is the current stock price of Traws Pharma (TRAW)?
What is the market cap of Traws Pharma (TRAW)?
